Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Overnight switch from rasagiline to safinamide in fluctuating Parkinson's disease
2016-000973-19Phase 4Completed
- Sponsor
- IRCCS San Raffaele Pisana
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of safinamide in Parkinson's disease (PD), sponsored by IRCCS San Raffaele Pisana. Primary endpoint: Change in mean blood pressure after switch. Started Jan 2022; status: completed.
02
Drugs
safinamide
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2016-000973-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000973-19.